No. At this time, these tests are not included in the COL-E measure or its value sets and we cannot predict if or when sRNA type tests will be added.
NCQA relies on a broad body of scientific evidence and guidance from multiple independent clinical guideline bodies when developing and updating quality measures. These include, but are not limited to, recommendations from the U.S. Preventive Services Task Force (USPSTF), as well as other national organizations. NCQA monitors emerging screening concepts and reviews evidence as it becomes available through its established measure development processes.
Because of this, while some tests may receive FDA authorization and are covered under certain CMS policies, they are not automatically included in our measures. NCQA will continue to review the guidelines and scientific literature, and communicate changes if they are made.